• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AMATORUS WOUND GUARD Passes all Antimicrobial Efficacy Testing

By: Press Release Distribution Service
April 19, 2026 at 10:29 AM EDT
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

nearly four years of testing against bacteria, fungi, and viruses passes every test.

United States, April 19, 2026 -- Amatorus announced Thursday, after nearly four years of development and a battery of European efficacy tests. Specifically, the product met BS EN standards for killing off bacteria, fungi, and viruses—a baseline requirement for any company trying to sell infection-prevention tools to the healthcare market.

Amatorus has already had their lipstick which kills herpes approved by the MHRA and is now a Class 1 Medical Device. The Amatorus Lip Shield was invented to stop infection transmission between adults and babies which according to the WHO is 50% of under 5 year old.

While Class I is the MHRA’s designation for low-risk devices, the registration is a necessary gatekeeper for any manufacturer looking to move product through UK clinical channels. For Amatorus, it’s a shift from the lab to the market.

"This was about discipline," a company spokesperson said, noting that the registration validates the product's safety . "The goal was meeting those BS EN standards while making sure the formulation actually held up under medical device requirements. It’s been a long process, but now we can move to production."

The testing wasn't just a formality. The product had to prove its "triple action" claim against a range of pathogens. According to the company, the formula manages to hit these efficacy marks without relying on added chemical agents—a detail they’re leaning on to differentiate themselves in a crowded field. “We consider our product so far advanced that it is the Apple to Blackberry of wound care treatments,” added the spokesperson.

Wound care remains a massive, and expensive, headache for hospitals. In the U.S. alone, complications from infected wounds drain tens of billions of dollars from the healthcare system every year. By securing the MHRA nod, Amatorus is betting that its focus on antimicrobial resistance will resonate with providers looking to cut those costs and risks.

With the paperwork filed and the registration active, the company says it’s now moving into the distribution phase, looking for partners across the UK and in the near future, other regions with similar regulatory setups.

About Amatorus

Amatorus is a medical device firm centered on infection prevention. The company develops validated technologies aimed at mitigating viral, bacterial, and fungal risks within professional healthcare environments.

Amatorus said it is already applying for its FDA 510K and once approved, the company is set to begin distribution to hospitals and clinics that have already made pre-orders in the USA.

Contact Info:
Name: david stickland
Email: Send Email
Organization: AMATORUS WOUND GUARD
Website: http://amatorus.com/

Release ID: 89188860

Should any problems, inaccuracies, or doubts arise from the content contained within this press release, we kindly request that you inform us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our dedicated team will promptly address your concerns within 8 hours, taking necessary steps to rectify identified issues or assist with the removal process. Providing accurate and dependable information is at the core of our commitment to our readers.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More
News headline image
The Cannabis Sector's Billion-Dollar Tax Cut ↗
April 23, 2026
Via MarketBeat
Topics Cannabis
Tickers CRLBF CURLF GTBIF TCNNF TLRY VRNOF
News headline image
USA Rare Earth's $2.8B Power Play to Secure the Supply Chain ↗
April 23, 2026
Via MarketBeat
Tickers USAR
News headline image
More Than Just Dirt: Caterpillar Is the AI Stock Nobody Saw Coming ↗
April 23, 2026
Via MarketBeat
Topics Artificial Intelligence
Tickers CAT
News headline image
Ternus the Page: Apple's Engineering Prodigy Takes the Reins ↗
April 23, 2026
Via MarketBeat
Tickers AAPL BRK BRK-B DIS KO TSM
News headline image
3 AI Small-Cap Stocks With Strong Insider and Institutional Buy-In ↗
April 23, 2026
Via MarketBeat
Topics Artificial Intelligence
Tickers KLTR LAW THRY

Recent Quotes

View More
Symbol Price Change (%)
AMZN  255.08
+0.00 (0.00%)
AAPL  273.43
+0.00 (0.00%)
AMD  305.33
+0.00 (0.00%)
BAC  52.47
+0.00 (0.00%)
GOOG  337.75
+0.00 (0.00%)
META  659.15
+0.00 (0.00%)
MSFT  415.75
+0.00 (0.00%)
NVDA  199.64
+0.00 (0.00%)
ORCL  176.28
+0.00 (0.00%)
TSLA  373.72
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap